Jascayd is an orally administered small-molecule therapy indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. It works by inhibiting multiple fibrotic and inflammatory signaling pathways involved in lung tissue scarring, thereby slowing disease progression and preserving pulmonary function. Through targeted modulation of fibroblast activity and reduction of extracellular matrix deposition, Jascayd helps mitigate the decline in lung capacity characteristic of IPF. Administered once daily, it offers a convenient and well-tolerated treatment option aimed at improving quality of life and long-term outcomes for patients living with this chronic and progressive lung disease.